HK1099216A1 - a-AMINOAMIDE DERIVATIVES USEFUL IN THE TREATMENT OF RESTLESS LEGS SYNDROME AND ADDICTIVE DISORDERS - Google Patents

a-AMINOAMIDE DERIVATIVES USEFUL IN THE TREATMENT OF RESTLESS LEGS SYNDROME AND ADDICTIVE DISORDERS

Info

Publication number
HK1099216A1
HK1099216A1 HK07106351.3A HK07106351A HK1099216A1 HK 1099216 A1 HK1099216 A1 HK 1099216A1 HK 07106351 A HK07106351 A HK 07106351A HK 1099216 A1 HK1099216 A1 HK 1099216A1
Authority
HK
Hong Kong
Prior art keywords
treatment
addictive disorders
derivatives useful
restless legs
legs syndrome
Prior art date
Application number
HK07106351.3A
Other languages
English (en)
Inventor
Claudia Besana
Elena Barbanti
Emanuela Izzo
Florian Thaler
Ruggero Fariello
Patricia Salvati
Luca Benatti
Original Assignee
Newron Pharm Spa
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Newron Pharm Spa filed Critical Newron Pharm Spa
Publication of HK1099216A1 publication Critical patent/HK1099216A1/xx

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/16—Amides, e.g. hydroxamic acids
    • A61K31/165—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
    • A61K31/197—Carboxylic acids, e.g. valproic acid having an amino group the amino and the carboxyl groups being attached to the same acyclic carbon chain, e.g. gamma-aminobutyric acid [GABA], beta-alanine, epsilon-aminocaproic acid or pantothenic acid
    • A61K31/198—Alpha-amino acids, e.g. alanine or edetic acid [EDTA]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/38—Heterocyclic compounds having sulfur as a ring hetero atom
    • A61K31/381—Heterocyclic compounds having sulfur as a ring hetero atom having five-membered rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A61P25/32—Alcohol-abuse
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A61P25/34—Tobacco-abuse
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A61P25/36—Opioid-abuse
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Organic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Addiction (AREA)
  • Psychiatry (AREA)
  • Psychology (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Heterocyclic Compounds Containing Sulfur Atoms (AREA)
HK07106351.3A 2004-04-22 2007-06-13 a-AMINOAMIDE DERIVATIVES USEFUL IN THE TREATMENT OF RESTLESS LEGS SYNDROME AND ADDICTIVE DISORDERS HK1099216A1 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP04009532A EP1588704A1 (en) 2004-04-22 2004-04-22 Alpha-aminoamide derivatives useful in the treatment of restless legs syndrome and addictive disorders
PCT/EP2005/004166 WO2005102300A1 (en) 2004-04-22 2005-04-19 α-AMINOAMIDE DERIVATIVES USEFUL IN THE TREATMENT OF RESTLESS LEGS SYNDROME AND ADDICTIVE DISORDERS

Publications (1)

Publication Number Publication Date
HK1099216A1 true HK1099216A1 (en) 2007-08-10

Family

ID=34924693

Family Applications (1)

Application Number Title Priority Date Filing Date
HK07106351.3A HK1099216A1 (en) 2004-04-22 2007-06-13 a-AMINOAMIDE DERIVATIVES USEFUL IN THE TREATMENT OF RESTLESS LEGS SYNDROME AND ADDICTIVE DISORDERS

Country Status (26)

Country Link
US (2) US8445513B2 (he)
EP (3) EP1588704A1 (he)
JP (1) JP5020069B2 (he)
KR (2) KR101238377B1 (he)
CN (1) CN1942179B (he)
AT (2) ATE494890T1 (he)
AU (1) AU2005235428B2 (he)
BR (2) BR122020004541B1 (he)
CA (1) CA2563674C (he)
CY (2) CY1108494T1 (he)
DE (2) DE602005009162D1 (he)
DK (2) DK1737438T3 (he)
ES (2) ES2313330T3 (he)
HK (1) HK1099216A1 (he)
HR (2) HRP20080593T3 (he)
IL (1) IL178732A (he)
ME (2) ME01219B (he)
MX (1) MXPA06012163A (he)
NO (2) NO337900B1 (he)
NZ (1) NZ550664A (he)
PL (2) PL1900362T3 (he)
PT (2) PT1900362E (he)
RS (2) RS51791B (he)
RU (1) RU2403030C2 (he)
SI (2) SI1737438T1 (he)
WO (1) WO2005102300A1 (he)

Families Citing this family (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB9727523D0 (en) 1997-12-31 1998-02-25 Pharmacia & Upjohn Spa Alpha-aminoamide derivatives useful as analgesic agents
PT1423168E (pt) * 2001-09-03 2006-05-31 Newron Pharm Spa Composicao farmaceutica que compreende gabapentina ou um seu analogo e uma x-aminoamida e a sua utilizacao como analgesico
EP1438956A1 (en) * 2003-01-16 2004-07-21 Newron Pharmaceuticals S.p.A. Alpha-aminoamide derivatives useful as antimigraine agents
ATE457724T1 (de) * 2003-08-25 2010-03-15 Newron Pharm Spa Alpha-aminoamid derivate zur verwendung als anti- inflammatorische wirkstoffe
EP1588704A1 (en) 2004-04-22 2005-10-26 Newron Pharmaceuticals S.p.A. Alpha-aminoamide derivatives useful in the treatment of restless legs syndrome and addictive disorders
KR101277520B1 (ko) * 2004-09-10 2013-06-21 뉴론 파마슈티칼즈 에스. 피. 에이. （할로벤질옥시）벤질아미노－프로판아미드를 포함하는 선택적 나트륨 및／또는 칼슘 채널 조절제로서 유용한 약제학적 조성물
US20060173074A1 (en) * 2004-11-10 2006-08-03 Juha Ellmen Treatment of restless legs syndrome
CA2629065C (en) * 2005-12-22 2013-08-06 Newron Pharmaceuticals S.P.A. 2 -phenylethylamino derivatives as calcium and/or sodium channel modulators
CN101442997B (zh) * 2006-04-03 2012-11-14 泰华制药工业有限公司 雷沙吉兰用于治疗多动腿综合征
EP1870097A1 (en) 2006-06-15 2007-12-26 Newron Pharmaceuticals S.p.A. Alpha-aminoamide derivatives useful in the treatment of cognitive disorders
CN101472880B (zh) * 2006-06-19 2013-04-24 纽朗制药有限公司 生产2-[4-(3-和2-氟苄氧基)苄氨基]丙酰胺类的方法
GB0706630D0 (en) * 2007-04-04 2007-05-16 Glaxo Group Ltd Novel compounds
MX2009013119A (es) 2007-06-15 2010-03-04 Newron Pharm Spa Derivados de 2-[2-(fenil)etilamino]alcanamida sustituidos y su uso como moduladores del canal de sodio y/o potasio.
DK2229351T3 (en) * 2007-12-11 2018-01-22 Newron Pharm Spa PROCEDURE FOR THE PREPARATION OF 2- [4- (3- OR 2-FLUORBENZYLOXY) BENZYLAMINO] PROPANAMIDS WITH HIGH PURITY
BRPI0821026A2 (pt) * 2007-12-19 2015-06-16 Newron Pharmaceutical S P A Derivados de alfa-minoamidas úteis no tratamento de transtornos psiquiátricos
EP2314569A1 (en) 2009-10-22 2011-04-27 Merck Patent GmbH Novel polymorphic forms of (S)-2-[4-(3-Fluoro-benzyloxy)-benzylamino]-propionamide mesylate salt and processes of manufacturing thereof
DK2563355T3 (en) 2010-04-27 2016-09-12 Newron Pharm Spa A process for the preparation of ralfinamide-methanesulphonate or R-enantiomers thereof.
US11278651B2 (en) 2018-10-17 2022-03-22 Gambro Lundia Ab Membrane and device for treating restless leg syndrome
CN114667963B (zh) * 2020-12-24 2024-04-26 中国科学院脑科学与智能技术卓越创新中心 一种非人灵长类动物药物成瘾性评估的装置

Family Cites Families (29)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB1140748A (en) 1966-06-23 1969-01-22 Ici Ltd New carboxylic acid derivatives
US4049663A (en) * 1972-06-06 1977-09-20 Allen & Hanburys Limited Ethylene diamine derivatives
FR2480747A1 (fr) * 1980-04-17 1981-10-23 Roques Bernard Derives d'acides amines et leur application therapeutique
US4935429A (en) * 1985-10-25 1990-06-19 Dackis Charles A Method of treating psychostimulant addiction
DE58905201D1 (de) * 1988-03-01 1993-09-16 Birkmayer Walther Mittel zur behandlung des parkinson-syndroms.
IL94466A (he) * 1989-05-25 1995-01-24 Erba Carlo Spa תכשירי רוקחות המכילים תולדות a-אמינו קרבוקסאמיד n-פנילאלקיל מותמרות תרכובות חדשות כאלה והכנתן
US5221536A (en) * 1990-05-07 1993-06-22 Alza Corporation Dosage form indicated for the management of abnormal posture, tremor and involuntary movement
EP0520325A1 (de) * 1991-06-28 1992-12-30 F.Hoffmann-La Roche & Co. Aktiengesellschaft Verwendung von Monoaminoxidase-B-Hemmern zur Verhütung und Behandlung von Entzugserscheinungen nach Alkohol- und Drogenmissbrauch
GB9306886D0 (en) 1993-04-01 1993-05-26 Erba Carlo Spa Substituted (arylakoxybenzyl) aminopropanamide derivatives and process for their preparation
IL111240A (en) * 1993-10-18 2001-10-31 Teva Pharma Salts of r(+) - enantiomers of n- propargyl-1-aminoindan and pharmaceutical compositions comprising them
DK0828513T3 (da) * 1995-05-26 2004-04-13 Pfizer Kombinationspræparater til behandling af parkinsonisme, indeholdende selektive NMDA-antagonister
WO1997000511A1 (de) 1995-06-17 1997-01-03 Baumann Guenter Scheibenkörper
GB9515412D0 (en) 1995-07-27 1995-09-27 Pharmacia Spa 2-(4-substituted)-benzylamino-2-methyl-propanamide derivatives
GB9515411D0 (en) 1995-07-27 1995-09-27 Pharmacia Spa N-(4-substituted-benzyl)-2-aminolactam derivatives
GB9727523D0 (en) 1997-12-31 1998-02-25 Pharmacia & Upjohn Spa Alpha-aminoamide derivatives useful as analgesic agents
GB9727521D0 (en) 1997-12-31 1998-02-25 Pharmacia & Upjohn Spa Substituted 2-benzylamino-2-phenyl-acetamide compounds
AU761457B2 (en) 1998-01-12 2003-06-05 Deborah Wenzel An additive composition also used as a fuel composition comprising water soluble alcohols
FI109453B (fi) * 1999-06-30 2002-08-15 Orion Yhtymae Oyj Farmaseuttinen koostumus
AU1359801A (en) * 1999-11-05 2001-06-06 Vela Pharmaceuticals Inc. Methods and compositions for treating reward deficiency syndrome
AU2080201A (en) * 1999-12-10 2001-06-18 University Of Cincinnati, The Treatment of addiction disorders
US20020019421A1 (en) * 2000-07-05 2002-02-14 Roni Biberman Compositions and therapy for substance addiction
CA2450315A1 (en) * 2001-06-13 2002-12-19 The Regents Of The University Of Michigan Dopamine receptor ligands and therapeutic methods based thereon
PL212708B1 (pl) * 2002-05-29 2012-11-30 Hoffmann La Roche Pochodne N-acyloaminobenzenu, sposób ich wytwarzania, lek zawierajacy te pochodne i zastosowanie pochodnych N-acyloaminobenzenu
PL203763B1 (pl) 2002-06-24 2009-11-30 Rockwool Int Sposób i urządzenie do wytwarzania wełny mineralnej
US6900354B2 (en) * 2002-07-15 2005-05-31 Hoffman-La Roche Inc. 3-phenyl-propionamido, 3-phenyl-acrylamido and 3-phenyl-propynamido derivatives
AR044007A1 (es) 2003-04-11 2005-08-24 Newron Pharmaceuticals Inc Metodos para el tratamiento de la enfermedad de parkinson
JP2005060370A (ja) * 2003-07-25 2005-03-10 Kyowa Hakko Kogyo Co Ltd 医薬組成物
EP1524267A1 (en) * 2003-10-15 2005-04-20 Newron Pharmaceuticals S.p.A. Substituted benzylaminoalkylene heterocycles
EP1588704A1 (en) 2004-04-22 2005-10-26 Newron Pharmaceuticals S.p.A. Alpha-aminoamide derivatives useful in the treatment of restless legs syndrome and addictive disorders

Also Published As

Publication number Publication date
ATE494890T1 (de) 2011-01-15
NZ550664A (en) 2010-08-27
NO20150971L (no) 2006-11-22
IL178732A (he) 2013-01-31
US20130217747A1 (en) 2013-08-22
PL1737438T3 (pl) 2009-01-30
EP1737438A1 (en) 2007-01-03
WO2005102300A1 (en) 2005-11-03
NO338870B1 (no) 2016-10-31
PT1900362E (pt) 2011-03-09
PL1900362T3 (pl) 2011-06-30
ES2313330T3 (es) 2009-03-01
ES2357559T3 (es) 2011-04-27
AU2005235428A1 (en) 2005-11-03
HRP20110230T1 (hr) 2011-04-30
JP5020069B2 (ja) 2012-09-05
KR101195819B1 (ko) 2012-11-05
RS50667B (sr) 2010-06-30
KR101238377B1 (ko) 2013-03-04
ME01219B (me) 2013-06-20
CY1111656T1 (el) 2015-10-07
PT1737438E (pt) 2008-12-22
EP1900362B1 (en) 2011-01-12
RS51791B (en) 2011-12-31
RU2006137079A (ru) 2008-04-27
CY1108494T1 (el) 2014-04-09
BRPI0509976B1 (pt) 2020-10-06
RU2403030C2 (ru) 2010-11-10
DE602005025941D1 (de) 2011-02-24
BRPI0509976B8 (pt) 2021-05-25
DK1900362T3 (da) 2011-05-09
EP1737438B1 (en) 2008-08-20
SI1900362T1 (sl) 2011-03-31
KR20120028399A (ko) 2012-03-22
MXPA06012163A (es) 2007-01-17
NO20064732L (no) 2006-11-22
ME02324B (me) 2016-06-20
ATE405256T1 (de) 2008-09-15
CA2563674C (en) 2012-12-18
BRPI0509976A (pt) 2007-10-16
US8445513B2 (en) 2013-05-21
US20070203182A1 (en) 2007-08-30
SI1737438T1 (sl) 2008-12-31
EP1900362A2 (en) 2008-03-19
IL178732A0 (en) 2007-05-15
JP2007533691A (ja) 2007-11-22
CN1942179A (zh) 2007-04-04
BR122020004541B1 (pt) 2021-11-09
DK1737438T3 (da) 2008-12-08
EP1588704A1 (en) 2005-10-26
EP1900362A3 (en) 2009-04-01
DE602005009162D1 (de) 2008-10-02
NO337900B1 (no) 2016-07-04
AU2005235428B2 (en) 2010-03-18
CA2563674A1 (en) 2005-11-03
US8697738B2 (en) 2014-04-15
CN1942179B (zh) 2010-08-11
HRP20080593T3 (en) 2008-12-31
KR20070042914A (ko) 2007-04-24

Similar Documents

Publication Publication Date Title
HK1099216A1 (en) a-AMINOAMIDE DERIVATIVES USEFUL IN THE TREATMENT OF RESTLESS LEGS SYNDROME AND ADDICTIVE DISORDERS
EP1948675A4 (en) METHOD AND COMPOSITIONS FOR TREATING MARFAN SYNDROME AND RELATED DISEASES
IL179508A0 (en) 2-substituted-4- heteroaryl-pyrimidines useful for the treatment of proliferative disorders
IL180205A0 (en) Quinazolin - 4 - yl - piperidine and cinnolin - 4 - yl - piperidine derivatives as pde10 inhibitors for the treatment of cns disorders
HK1112241A1 (en) Substituted pyridinyl and pyrimidinyl derivatives as modulators of metabolism and the treatment of disorders related thereto
WO2007064797A3 (en) Inhibitors of c-met and uses thereof
NO20070049L (no) Pyrrolotriazinderivater anvendelig for behandling av hyperproliferative forstyrrelser og sykdommer assosiert med angiogenese
PL1919466T3 (pl) Formulacje do leczenia nieprawidłowości lipoproteinowych obejmujące statynę i pochodną metylonikotynoamidu
NO20063368L (no) Alfa-aminoamid-derivater anvendelige ved behandling av lidelser i nedre urinveier
IL189009A0 (en) Methods and compositions for the treatment of neuropathies and related disorders
WO2007055804A3 (en) Methods and compositions for administration of iron for the treatment of restless leg syndrome
IL188390A0 (en) Imidazolyl-pyrimidine compounds for use in the treatment of proliferative disorders
PL1879585T3 (pl) Zastosowanie pochodnych pirymidyloaminobenzamidowych do leczenia mastocytozy układowej
MXPA05011699A (es) Inhibidores de la bomba de protones para el tratamiento de trastornos del abdomen inferior.
EP1937242A4 (en) METHOD AND COMPOSITIONS FOR THE TREATMENT OF NEUROPSYCHIATRIC DISEASES AND ADDITIVES
ZA200800409B (en) Imidazolyl-pyrimidine compounds for use in the treatment of proliferative disorders
EP1941894A4 (en) COMPOSITION OF ISOFLAVONES FOR THE TREATMENT OF MENOPAUSE SYMPTOMS AND PHYSIOLOGICAL DISORDERS
GB0807094D0 (en) 4,4-dimethylpiperidine-2, 6-dione derivatives for use in the treatment of hypertension
WO2006077146A3 (de) Verfahren zur herstellung von albumin-konjugaten mit gyrasehemmern
WO2007009700A3 (en) Use of substituted pyrazoline compounds for the treatment of the lipid parameters of the metabolic syndrome